{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-010035","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.185861+00:00","generated_at":"2026-05-24T22:32:17.988001+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BriaPro Therapeutics (2/3 owned by BriaCell) reports six-month net loss of $233K, cash only $1, going concern warning","bullets":["Net loss for six months ended Jan 31, 2025: $233,185; accumulated deficit $673,394.","Cash and cash equivalents only $1; total assets $192,161 mostly intangible patents.","Current liabilities $658,049 due to related party (BriaCell); warrant liability $172,991.","No revenue; R&D expenses $130,023, G&A $80,012 for six months.","Going concern warning: material uncertainty about ability to raise capital to continue operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-010035","json":"https://secwatch.observer/filing/0001493152-25-010035.json","markdown":"https://secwatch.observer/filing/0001493152-25-010035.md","text":"https://secwatch.observer/filing/0001493152-25-010035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315225010035/0001493152-25-010035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315225010035/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:32:17.988001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}